Melanoma patient staging: Histopathological versus molecular evaluation of the sentinel node

Melanoma Research

Volumn 13, Issue 3, 2003, Pages 313-324

  Davids, Virginia ^a   Kidson, Susan H ^a   Hanekom, Gideon S ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Histology; Melanoma; Metastasis; Prognosis; Reverse transcription polymerase chain reaction; Sentinel lymph node; Staging

Indexed keywords

MOLECULAR MARKER; TUMOR MARKER;

AMPLICON; CANCER RECURRENCE; CANCER STAGING; CELL HETEROGENEITY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; ETHICS; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MOLECULAR BIOLOGY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA DEGRADATION; RNA EXTRACTION; SCHWANN CELL; SENTINEL LYMPH NODE; TISSUE HOMOGENATE;

HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; NEOPLASM PROTEINS; NEOPLASM STAGING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038517701     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200306000-00015     Document Type: Review

References (131)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-3648.
2. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 1997; 225:1-14.
3. Cascinelli N, Belli F, Santinami M, Fait V, Testori A, Ruka W, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7:469-474.
4. Cochran AJ, Pihl E, Wen DR, Hoon DS, Korn EL. Zoned immune suppression of lymph nodes draining malignant melanoma: histotogic and immunohistotogic studies. J Natl Cancer Inst 1987; 78:399-405.
5. Wang X, Heller R, VanVoorhis N, Cruse CW, Glass F, Fenske N, et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg 1994; 220:768-774.
6. van Diest PJ, Peterse HL, Borgstein PJ, Hoekstra O, Meijer CJ. Pathological investigation of sentinel lymph nodes. Eur J Nucl Med 1999; 26:S43-49.
7. Rankin EM. Detection of early micrometastases in malignant melanoma. Eur J Cancer 1996; 32A:1627-1629.
8. Treseier PA, Tauchi PS. Pathologic analysis of the sentinel lymph node. Surg Clin North Am 2000; 80:1695-1719.
9. Stojadinovic A, Allen PJ, Clary BM, Busam KJ, Coit DG. Value of frozen-section analysis of sentinel lymph nodes for primary cutaneous malignant melanoma. Ann Surg 2002; 235:92-98.
10. Cochran AJ. Melanoma metastases through the lymphatic system. Surg Clin North Am 2000; 80:1683-1693.
11. Baisden BL, Askin FB, Lange JR, Westra WH. HMB-45 immunohisto-chemical staining of sentinel lymph nodes: a specific method for enhancing detection of micrometastases in patients with melanoma. Am J Surg Pathol 2000; 24:1140-1146.
12. Yu LL, Flotte TJ, Tanabe KK, Gadd MA, Cosimi AB, Sober AJ, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. Cancer 1999; 86:617-627.
13. Goeminne JC, Guillaume T, Symann M. Pitfalls in the detection of disseminated non-hematological tumor cells. Ann Oncol 2000; 11:785-792.
14. Natsugoe S, Mueller J, Stein HJ, Feith M, Hofler H, Siewert JR. Micrometastasis and tumor cell microinvolvement of lymph nodes from esophageal squamous cell carcinoma: frequency, associated tumor characteristics, and impact on prognosis. Cancer 1998; 83:858-866.
15. Dowlatshahi K, Fan M, Snider HC, Habib FA. Lymph node micrometastases from breast carcinoma: reviewing the dilemma. Cancer 1997; 80:1188-1197.
16. Hatta N, Takata M, Takehara K, Ohara K. Polymerase chain reaction and immunohistochemistry frequently detect occult melanoma cells in regional lymph nodes of melanoma patients. J Clin Pathol 1998; 51:597-601.
17. Prota G. Recent advances in the chemistry of melanogenesis in mammals. J Invest Dermatol 1980; 75:122-127.
18. Shivers SC, Wang X, Li W, Joseph E, Messina J, Glass LF, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280:1410-1415.
19. Walts AE, Said JW, Shintaku IP. Cytodiagnosis of malignant melanoma. Immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis. Am J Clin Pathol 1988; 90:77-80.
20. Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999; 23:686-690.
21. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, et al. Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother Emphasis Tumor Immunol 1996; 19:192-205.
22. Scheibenbogen C, Weyers I, Ruiter D, Willhauck M, Bittinger A, Keilholz U. Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J Immunother Emphasis Tumor Immunol 1996; 19:375-380.
23. de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Brocker EB, Renard N, et al. Expression of gp100, MART-1, tyresinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group. J Pathol 2001; 193:13-20.
24. Kaufmann O, Koch S, Burghardt J, Audring H, Dietel M. Tyrosinase, melan-A, and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 1998; 11:740-746.
25. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75:517-524.
26. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994; 91:6458-6462.
27. Brouwenstijn N, Slager EH, Bakker AB, Schreurs MW, Van der Spek CW, Adema GJ, et al. Transcription of the gene encoding melanoma-associated antigen gp100 in tissues and cell lines other than those of the melanocytic lineage. Br J Cancer 1997; 76:1562-1566.
28. Novocastra Product Catalogue 2000. Novocastra Laboratories Ltd. Newcastte-upon-Tyne, 2000; pp. 53-64.
29. Fetsch PA, Marincola FM, Abati A. The new melanoma markers: MART-1 and Melan-A (the NIH experience). Am J Surg Pathol 1999; 23:607-610.
30. Hofbauer GF, Schaefer C, Noppen C, Boni R, Kamarashev J, Nestle FO, et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997; 151:1549-1553.
31. Beaty MW, Fetsch P, Wilder AM, Marincola F, Abati A. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer 1997; 81:57-63.
32. Basarab T, Picard JK, Simpson E, Russell-Jones R. Melanoma antigen-encoding gene expression in melanocytic naevi and cutaneous malignant melanomas. Br J Dermatol 1999; 140:106-108.
33. Clarkson KS, Sturdgess IC, Molyneux AJ. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A). J Clin Pathol 2001; 54:196-200.
34. Li W, Stall A, Shivers SC, Lin J, Haddad F, Messina J, et al. Clinical relevance of molecular staging for melanoma: comparison of RT-PCR and immunohistochemistry staining in sentinel lymph nodes of patients with melanoma. Ann Surg 2000; 231:795-803.
35. Carson KF, Wen DR, Li PX, Lana AM, Bailly C, Morton DL, et al. Nodal nevi and cutaneous melanomas. Am J Surg Pathol 1996; 20:834-840.
36. Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang HJ, Elashoff R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17:3238-3244.
37. Smith B, Selby P, Southgate J, Pittman K, Bradley C, Blair GE. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338:1227-1229.
38. Bieligk SC, Ghossein R, Bhattacharya S, Coit DG. Detection of tyrosinase mRNA by reverse transcription-polymerase chain reaction in melanoma sentinel nodes. Ann Surg Oncol 1999; 6:232-240.
39. Calogero A, Timmer-Bosscha H, Schraffordt Koops H, Tiebosch AT, Mulder NH, Hospers GA. Limitations of the nested reverse transcriptase polymerase chain reaction on tyrosinase for the detection of malignant melanoma micrometastases in lymph nodes. Br J Cancer 2000; 83:184-187.
40. Lockett MA, Metcalf JS, Baron PL, PH OB, Elliott BM, Robison JG, et al. Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastatic disease in axillary lymph nodes of breast cancer patients. Am Surg 1998; 64:539-543, discussion 543-544.
41. Luketich JD, Kassis ES, Shriver SP, Nguyen NT, Schauer PR, Weigel TL, et al. Detection of micrometastases in histologically negative lymph nodes in esophageal cancer. Ann Thorac Surg 1998; 66:1715-1718.
42. Okegawa T, Nutahara K, Higashihara E. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 2000; 163:1183-1188.
43. Futamura M, Takagi Y, Koumura H, Kida H, Tanemura H, Shimokawa K, et al. Spread of colorectal cancer micrometastases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoem-bryonic antigen and cytokeratin 20. J Surg Oncol 1998; 68:34-40.
44. van Houten VM, Tabor MP, van den Brekel MW, Denkers F, Wishaupt RG, Kummer JA, et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res 2000; 6:3803-3816.
45. Ghossein RA, Bhattacharya S. Molecular detection and characterisation of circulating tumour cells and micrometastases in solid tumours. Eur J Cancer 2000; 36:1681-1694.
46. Pittman K, Burchill S, Smith B, Southgate J, Joffe J, Gore M, et al. Reverse transcriptase-polymerase chain reaction for expression of tyrosinase to identify malignant melanoma cells in peripheral blood. Ann Oncol 1996; 7:297-301.
47. Hanekom GS, Stubbings HM, Johnson CA, Kidson SH. The detection of circulating melanoma cells correlates with tumour thickness and ulceration but is not predictive of metastasis for patients with primary melanoma. Melanoma Res 1999; 9:465-473.
48. Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, et al. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group. Eur J Cancer 1998; 34:750-753.
49. Schittek B, Blaheta HJ, Florchinger G, Sauer B, Garbe C. Increased sensitivity for the detection of malignant melanoma cells in peripheral blood using an improved protocol for reverse transcription-polymerase chain reaction. Br J Dermatol 1999; 141:37-43.
50. Davids V, Kidson SH, Hanekom GS. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate. Mol Pathol 2003; 55:43-51.
51. de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer 1999; 80:883-891.
52. Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, et al. Evolution of the functional human beta-actin gene and its multi-pseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 1985; 5:2720-2732.
53. Piechaczyk M, Blanchard JM, Riaad-El Sabouty S, Dani C, Marty L, Jeanteur P. Unusual abundance of vertebrate 3-phosphate dehydrogenase pseudogenes. Nature 1984; 312:469-471.
54. Taylor JJ, Heasman PA. Control genes for reverse transcriptase/polymerase chain reaction (RT-PCR). Br J Haematol 1994; 86:444-445.
55. Freeman WM, Walker SJ, Vrana KE. Quantitative RT-PCR: pitfalls and potential. Biotechniques 1999; 26:112-122, 124-125.
56. Schittek B, Bodingbauer Y, Ellwanger U, Blaheta HJ, Garbe C. Amplification of MelanA messenger RNA in addition to tyrosinase increases sensitivity of melanoma cell detection in peripheral blood and is associated with the clinical stage and prognosis of malignant melanoma. Br J Dermatol 1999; 141:30-36.
57. Le Bricon T, Stoitchkov K, Letellier S, Guibal F, Spy J, Garnier JP, et al. Simultaneous analysis of tyrosinase mRNA and markers of tyrosinase activity in the blood of patients with metastatic melanoma. Clin Chim Acta 1999; 282:101-113.
58. Jung FA, Buzaid AC, Woods KV, Ross M, Grimm EA. Detection of melanoma cells in peripheral blood using reverse transcription pelymerase chain reaction assay for tyrosinase mRNA. Cancer Surv 1996; 26:251-265.
59. Keilholz U. New prognostic factors in melanoma: mRNA tumour markers. Eur J Cancer 1998; 34 (suppl 3):S37-41.
60. Ghossein RA, Coit D, Brennan M, Zhang ZF, Wang Y, Bhattacharya S, et al. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin Cancer Res 1998; 4:419-428.
61. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science 1982; 217:998-1003.
62. Curry BJ, Myers K, Hersey P. MART-1 is expressed tess frequently on circulating melanoma cells in patients who develop distant compared with locoregional metastases. J Clin Oncol 1999; 17:2562-2571.
63. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999; 17:304-311.
64. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ, van Muijen GN. Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma Res 2001; 11:451-459.
65. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R, et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150:2143-2152.
66. Miyashiro I, Kuo C, Huynh K, Iida A, Morton D, Bilchik A, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor-specific MAGE-A genes. Clin Chem 2001; 47:505-512.
67. Sarantou T, Chi DD, Garrison DA, Conrad AJ, Schmid P, Morton DL, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res 1997; 57:1371-1376.
68. Van der Velde-Zimmermann D, Roijers JF, Bouwens-Rombouts A, De Weger RA, De Graaf PW, Tilanus MG, et al. Molecular test for the detection of tumor cells in blood and sentinel nodes of melanoma patients. Am J Pathol 1996; 149:759-764.
69. Blaheta HJ, Schittek B, Breuninger H, Maczey E, Kroeber S, Sotlar K, et al. Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry. Int J Cancer 1998; 79:318-323.
70. Blaheta HJ, Schittek B, Breuninger H, Sotlar K, Ellwanger U, Thelen MH, et al. Detection of melanoma micrometastasis in sentinel nodes by reverse transcription-polymerase chain reaction correlates with tumor thickness and is predictive of micrometastatic disease in the lymph node basin. Am J Surg Pathol 1999; 23:822-828.
71. Lukowsky A, Bellmann B, Ringk A, Winter H, Audring H, Fenske S, et al. Detection of melanoma micrometastases in the sentinel lymph node and in nonsentinel nodes by tyrosinase polymerase chain reaction. J Invest Dermatol 1999; 113:554-559.
72. Battayani Z, Xerri L, Hassoun J, Bonerandi JJ, Grob JJ. Tyrosinase gene expression in human tissues. Pigment Cell Res 1993; 6:400-405.
73. Schwurzer-Voit M, Proebstle TM, Sterry W. Identification of lymph node metastases by use of polymerase chain reaction (PCR) in melanoma patients. Eur J Cancer 1996; 32A:264-268.
74. O' Connell CD, Juhasz A, Kuo C, Reeder DJ, Hoon DS. Detection of tyrosinase mRNA in melanoma by reverse transcription-PCR and electrochemiluminescence. Clin Chem 1998; 44:1161-1169.
75. Muhlbauer M, Langenbach N, Stolz W, Hein R, Landthaler M, Buettner R, et al. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR. Clin Cancer Res 1999; 5:1099-1105.
76. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989; 339:237-238. Published erratum: Nature 1989; 339:490.
77. Sarkar G, Sommer SS. Shedding light on PCR contamination. Nature 1990; 343:27.
78. Belak S, Ballagi-Pordany A. Experiences on the application of the polymerase chain reaction in a diagnostic laboratory. Mol Cell Probes 1993; 7:241-248.
79. Walder RY, Hayes JR, Walder JA. Use of PCR primers containing a 3′-terminal ribose residue to prevent cross-contamination of amplified sequences. Nucleic Acids Res 1993; 21:4339-4343.
80. Verkaik NS, Schroder FH, Romijn JC. Clinical usefulness of RT-PCR detection of hematogenous prostate cancer spread. Urol Res 1997; 25:373-384.
81. Kreuzer KA, Lass U, Landt O, Nitsche A, Laser J, Ellerbrok H, et al. Highly sensitive and specific fluorescence reverse transcription-PCR assay for the pseudogene-free detection of beta-actin transcripts as quantitative reference. Clin Chem 1999; 45:297-300.
82. Chelly J, Concordet JP, Kaplan JC, Kahn A. Illegitimate transcription: transcription of any gene in any cell type. Proc Natl Acad Sci USA 1989; 86:2617-2621.
83. Kimoto Y. A single human cell expresses all messenger ribonucleic acids: the arrow of time in a cell. Mol Gen Genet 1998; 258:233-239.
84. Kaplan JC, Kahn A, Chelly J. Illegitimate transcription: its use in the study of inherited disease. Hum Mutat 1992; 1:357-360.
85. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, Hermans J, van Krieken JH, Cornelisse CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998; 339:223-228.
86. Schoenfeld A, Luqmani Y, Smith D, S OR, Shousha S, Sinnett HD, et al. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction. Cancer Res 1994; 54:2986-2990.
87. Haninec P, Vachtenheim J. Tyrosinase protein is expressed also in some neural crest derived cells which are not melanocytes. Pigment Cell Res 1988; 1:340-343.
88. Joseph E, Messina J, Glass FL, Cruse CW, Rapaport DP, Berman C, et al. Radioguided surgery for the ultrastaging of the patient with melanoma. Cancer J Sci Am 1997; 3:341-345.
89. McCarthy SW, Palmer AA, Bale PM, Hirst E. Naevus cells in lymph nodes. Pathology 1974; 6:351-358.
90. Ioachim HL. Epithelial cell inclusions in lymph nodes. In: Lymph Node Pathology. Ioachim HL (editor). Philadelphia: Lippincott, 1994; 44:297-304.
91. Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis JD, Silvapulle M, et al. MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma. Melanoma Res 2000; 10:259-264.
92. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001; 61:5544-5551.
93. Zendman AJ, van Kraats AA, den Hollander AI, Weidle UH, Ruiter DJ, van Muijen GN. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int J Cancer 2002; 97:195-204.
94. Weaver DL. Sentinel lymph node biopsy in breast cancer: creating controversy and defining new standards. Adv Anat Pathol 2001; 8:65-73.
95. van der Velde-Zimmermann D, Schipper ME, de Weger RA, Hennipman A, Borel Rinkes IH. Sentinel node biopsies in melanoma patients: a protocol for accurate, efficient, and cost-effective analysis by preselection for immunohistochemistry on the basis of Tyr-PCR. Ann Surg Oncol 2000; 7:51-54.
96. Goydos JS, Ravikumar TS, Germino FJ, Yudd A, Bancila E. Minimally invasive staging of patients with melanoma: sentinel lymphadenectomy and detection of the melanoma-specific proteins MART-1 and tyrosinase by reverse transeriptase polymerase chain reaction. J Am Coll Surg 1998; 187:182-188; discussion 188-190.
97. Blaheta HJ, Ellwanger U, Schittek B, Sotlar K, MacZey E, Breuninger H, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114:637-642.
98. Cochran AJ, Wen DR, Morton DL. Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol 1988; 12:612-618.
99. Florell SR, Coffin CM, Holden JA, Zimmermann JW, Gerwels JW, Summers BK, et al. Preservation of RNA for functional genomic studies: a multidisciplinary tumor bank protocol. Mod Pathol 2001; 14:116-128.
100. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17:976-983.
101. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001; 233:250-258.
102. Gadd MA, Cosimi AB, Yu J, Duncan LM, Yu L, Flotte TJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134:381-387.
103. Mackie RM. Malignant melanoma. In: Skin Cancer: An Illustrated Guide to the Etiology, Clinical Features, Pathology and Management of Benign and Malignant Cutaneous Tumors. London, UK, Martin Dunitz Ltd; 1996; pp. 183-205.
104. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
105. Cascinelli N, Morabito A, Santinami M, MacKie RM, Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998; 351:793-796.
106. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 2001; 19:2851-2855.
107. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16:2253-2260.
108. Joseph E, Brobeil A, Glass F, Glass J, Messina J, DeConti R, et al. Results of complete lymph node dissection in 83 melanoma patients with positive sentinel nodes. Ann Surg Oncol 1998; 5:119-125.
109. Reintgen D, Shivers S. Sentinel lymph node micrometastasis from melanoma. Proven methodology and evolving significance. Cancer 1999; 86:551-552.
110. Reeves ME, Coit DG. Melanoma. A multidisciplinary approach for the general surgeon. Surg Clin North Am 2000; 80:581-601.
111. Hatta N, Fujimoto A, Takehara K, Takata M. Mapping of occult melanoma micrometastases in the inguinal lymph node basin by immunohistochemistry and RT-PCR. Melanoma Res 1999; 9:401-406.
112. Wrightson WR, Wong SL, Edwards MJ, Chao C, Conrad AJ, Albrecht J, et al. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of nonsentinel nodes following completion lymphadenectomy for melanoma. J Surg Res 2001; 98:47-51.
113. McMasters KM. The Sunbelt Melanoma Trial. Ann Surg Oncol 2001; 8:41S-43S.
114. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000; 25:169-193.
115. Wagner JD, Gordon MS, Chuang TY, Coleman JJ III, Hayes JT, Jung SH, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer 2000; 89:453-462.
116. Morton DL, Thompson JF, Essner R, Elashoff R, Stern SL, Nieweg OE, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230:453-463, discussion 463-465.
117. Brady MS, Coit DG. Sentinel lymph node evaluation in melanoma. Arch Dermatol 1997; 133:1014-1020.
118. Dunn CL, Zitelli JA. Standards of care for patients with malignant melanoma. J Am Acad Dermatol 2000; 43:155-158.
119. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36:889-894.
120. Gilboa E. How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 1999; 48:382-385.
121. Sogn JA. Tumor immunology: the glass is half full. Immunity 1998; 9:757-763.
122. Barnhill RL. The biology of melanoma micrometastases. Recent Results Cancer Res 2001; 158:3-13.
123. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, et al. Multistep nature of metastatic inefficiency; dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153:865-873.
124. Radisky D, Hagios C, Bissell MJ. Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 2001; 11:87-95.
125. Barnhill RL, Piepkorn MW, Cochran AJ, Flynn E, Karaoli T, Folkman J. Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. Arch Dermatol 1998; 134:991-994.
126. Webb CP, Vande Woude GF. Genes that regulate metastasis and angiogenesis. J Neurooncol 2000; 50:71-87.
127. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1:149-153.
128. Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 1997; 79:2361-2370.
129. Pardoll DM. Cancer vaccines. Nat Med 1998; 4:525-531.
130. Monzavi-Karbassi B, Kieber-Emmons T. Current concepts in cancer vaccine strategies. Biotechniques 2001; 30:170-172, 174, 176 passim.
131. Pawelec G. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer? Cancer Immunol Immunother 1999; 48:343-345.